Overview
Financials
Revenue history
Filing timeliness
No financial statement for 2024 – the filing deadline has passed. 2 of 3 financial statements were filed late (the longest delay 94 days for 2021).
- 2024not filed
- 202329/07/2024
- 202229/06/2023
- 202117/10/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2023.
Results vs industry
Industry
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Maciej Paweł Ciemnyage 35 | 300 | $4,051.86 | 49.1803% |
Kamil Adam Mieszkowskiage 36 | 300 | $4,051.86 | 49.1803% |
Others | 10 | $135.06 | 1.6394% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 2, 2025 | Aid for research and development projects: industrial research | $1.6M$1,583,548 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 2, 2025 | Aid for research and development projects: experimental development | $66,546$66,546 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Feb 11, 2021 | Aid for SME access to finance — aid for start-ups | $30,186$30,186 | Fundacja Przedsiębiorczości Technologicznej |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-05 | A tool for high-throughput design of allosteric transmembrane peptides and peptidomimetics using unconventional GPCR binding strategies based on causal analysis of long-timescale molecular dynamics simulation trajectories | $1.8M$1,774,898 | European Funds for a Modern Economy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-11-24 | Share capital increase (5,000.00 PLN → 30,000.00 PLN) | |
| 2024-09-13 | Address change (Ul. Chmielna 73, 00-801, Warszawa → Ul. Bagatela 15/73, 00-585, Warszawa) | |
| 2023-01-10 | Address change (Ul. Dobra 56/66/16, 00-312, Warszawa → Ul. Chmielna 73, 00-801, Warszawa) | |
| 2021-02-09 | Entered in the register |
FAQ
Last updated: 2026-04-24